SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases

Exclusion criteria

• . Active hepatitis, cirrhosis, or Child-Pugh score Class B or C;
• . Extrahepatic metastases: bone or brain metastases, or ≥3 unresectable lung metastases (according to the 8th edition of the UICC);
• . Unmeasurable liver metastases;
• . History of severe drug allergies (including allergies to platinum agents, 5-FU, LV, and 5-HT3 receptor antagonists);
• . Patients who have participated in or are currently participating in other clinical trials within the past 4 weeks;
• . History of prior treatment with anti-PD-1, PD-L1, PD-L2, CTLA-4, or any other specific T-cell costimulatory or checkpoint pathway-targeted therapies;
• . Severe electrolyte abnormalities;
• . Presence of gastrointestinal diseases, such as active gastric or duodenal ulcers, ulcerative colitis, or unresected tumors with active bleeding; or other conditions that may lead to gastrointestinal bleeding or perforation (Note: Gastrointestinal fistulas that have not healed after surgical treatment, such as rectovesical, rectourethral, or rectovaginal fistulas, are exclusionary unless a stoma has been created and there are no active symptoms);